1. Home
  2. ALKT vs DMRA Comparison

ALKT vs DMRA Comparison

Compare ALKT & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alkami Technology Inc.

ALKT

Alkami Technology Inc.

HOLD

Current Price

$14.43

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

HOLD

Current Price

$20.77

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALKT
DMRA
Founded
2007
2011
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
ALKT
DMRA
Price
$14.43
$20.77
Analyst Decision
Buy
Strong Buy
Analyst Count
8
10
Target Price
$19.86
★ $46.89
AVG Volume (30 Days)
★ 2.0M
519.7K
Earning Date
10-28-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 121.48
EPS
★ N/A
N/A
Revenue
★ $152,159,000.00
N/A
Revenue This Year
$19.44
N/A
Revenue Next Year
$16.64
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 35.68
N/A
52 Week Low
$13.21
$16.50
52 Week High
$24.47
$34.89

Technical Indicators

Market Signals
Indicator
ALKT
DMRA
Relative Strength Index (RSI) 33.03 40.58
Support Level $13.21 $18.73
Resistance Level $14.52 $26.76
Average True Range (ATR) 0.48 1.36
MACD 0.13 0.16
Stochastic Oscillator 35.16 50.46

Price Performance

Historical Comparison
ALKT
DMRA

About ALKT Alkami Technology Inc.

Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: